Vnitr Lek 2011, 57(6):523-528

Změna spektra supraventrikulárních tachyarytmií indikovaných ke katetrové ablaci - editorial

R. Lábrová
Interní kardiologická klinika Lékařské fakulty MU a FN Brno, pracoviątě Bohunice, přednosta prof. MUDr. Jindřich ©pinar, CSc., FESC

Received: February 23, 2011; Published: June 1, 2011  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Lábrová R. Změna spektra supraventrikulárních tachyarytmií indikovaných ke katetrové ablaci - editorial. Vnitr Lek. 2011;57(6):523-528.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Baine WB, Yu W, Weis KA. Trends and outcomes in the hospitalization of older Americans for cardiac conduction disorders or arrhythmias, 1991-1998. J Am Geriatr Soc 2001; 49: 763-770. Go to original source... Go to PubMed...
    2. Blomström-Lundqvist C, Scheinman MM, Aliot ME et al. ACC/AHA/ESC Guidelines for the management of patients with supraventricular arrhythmias. A report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines. EHJ 2003; 24: 1857-1897. Go to original source...
    3. Fiala M. Doporučené postupy pro diagnostiku a léčbu supraventrikulárních tachyarytmií. Cor Vasa 2005; 47 (9 Suppl): 18-39.
    4. Wanless RS, Anderson K, Joy M et al. Multicenter comparative study of the efficacy and safety of sotalol in the profylactic treatment of patients with paroxysmal supraventricular tachyarrhythmias. Am Heart J 1997; 133: 441-446. Go to original source... Go to PubMed...
    5. Tendera M, Wnuk-Wojnar AM, Kulakowski P et al. Efficacy and safety of dofetilide in the prevention of symptomatic episode of paroxysmal supraventricular tachycardia: a 6 month double-blind comparison with propafenone and placebo. Am Heart J 2001: 142: 93-98. Go to original source... Go to PubMed...
    6. Garson A, Smith RT, Moak JP et al. Atrial automatic ectopic tachycardia in children. In: Tuboul P, Waldo AL (eds). Atrial Arrhythmias: Current Concepts and Management. St. Louis. Mo: Mosby Year Book 1990: 282-287.
    7. Chen SA, Chiang CE, Yang CJ et al. Sustained atrial tachycardia in adult patients. Electrophysiologic characteristics, pharmacological response, possible mechanisms, and effects of radiofrequency ablation. Circulation 1994; 90: 1262-1278. Go to original source... Go to PubMed...
    8. Jaïs P, Shah DC, Haïssaguerre M et al. Prospective randomized comparison of irrigated-tip versus conventional-tip catheters for ablation of common flutter. Circulation 2000; 101: 772-776. Go to original source... Go to PubMed...
    9. Lábrová R. Fibrilace síní v době katétrové ablace. Vnitř Lék 2010; 56: 871-879. Go to PubMed...
    10. Lábrová R, Fiala M, Toman O et al. Radiofrekvenční katetrová ablace paroxyzmální fibrilace síní konvenční metodou, bezprostřední a dlouhodobé výsledky. Vnitř Lék 2008; 54: 953-960. Go to PubMed...
    11. Lábrová R, ©pinar J. Katetrizační ablace fibrilace síní. Kardiol Rev 2008; 10: 103-110.
    12. European Heart Rhythm Association; European Association for Cardio-Thoracic Surgery, Camm AJ, Kirchhof P, Lip GY et al. Guidelines for the management of atrial fibrillation. The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010; 31: 2369-2429. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.